Brentuximab Vedotin PTCL

Barbara Pro, MD

Professor Of Medicine

Director of Lymphoma Program

Columbia University Irving Medical Center/New York- Presbyterian Hospital

→ NewYork-¬ Presbyterian

COLUMBIA UNIVERSITY MEDICAL CENTER

COLUMBIA COLUMBIA UNIVERSITY IRVING MEDICAL CENTER


Disclosures for Barbara Pro, MD


I have the following relevant financial relationship to disclose:

• Honoraria: Seattle Genetics, Secura Bio

CD30 Structure and Function


- CD30 is a cysteine-rich 120-kDa transmembrane protein that belongs to the family of tumor necrosis factor receptor (TNFR)
- Role of CD30 receptor is not fully elucidated: cell cycle arrest, apoptosis, and NFkB activation
- TRAF-5, TRAF-1, and TRAF-2 → stimulate NFkB





Brentuximab Vedotin (SGN-35, BV)

- Antibody-drug conjugate
- Potent anti-microtubule cytotoxic
- Chemically conjugated to monomethyl auristatin E by a dipeptide linker
- Stable in physiologic conditions and stable in human plasma, but cleaved selectively by lysosomal enzymes



ORIGINAL ARTICLE

BV: Phase 1 trial

- Phase 1, open-label, multicenter dose-escalation study,
- BV Dose:0.1 to 3.6 mg/kg every 3 weeks
- 45 patients with relapsed or refractory CD30-positive hematologic cancers
- -2 ALCL/1 AITL
- Patients had received a median of three previous chemotherapy regimens (range, 1-7), and 73% had undergone autologous stemcell transplantation.

Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas

Anas Younes, M.D., Nancy L. Bartlett, M.D., John P. Leonard, M.D., Dana A. Kennedy, Pharm.D., Carmel M. Lynch, Ph.D., Eric L. Sievers, M.D., and Andres Forero-Torres, M.D.


Response				1	Dose (mg	/kg)			
	0.1 (N=3)	0.2 (N=4)	0.4 (N=3)	0.6 (N=3)	0.8 (N=3)	1.2 (N=4)	1.8 (N=12)	2.7 (N=12)	3.6 (N=1)
Complete remission	0	0	0	0	0	1†	4	6†	0
Partial remission	0	0	0	2	0	1	2	1	0
Stable disease	2	0	2	1	2	2	5	5	0
Progressive disease	1	4‡	1	0	1	0	1	0	0
Could not be evaluated	0	0	0	0	0	0	0	0	1§

Optimal dosing of BV determined to be 1.8mg/kg IV every 3 weeks Objective response in 50% of HL patients Complete remission in 35% DOR – median 9.7 months


Younes et al NEJM 2010 Abid et al Annals of Hem 2016

Brentuximab vedotin in R/R sALCL

Table 2. Key Response Results per Independent Review




Brentuximab Vedotin Activity in a Phase 2 Study of R/R sALCL




•Patients with R/R ALCL who achieved CR with brentuximab vedotin had 79% OS and 57% PFS at 5 years, with median response duration not reached.

Pro B, et al. Blood 2017

CD30 Positivity in Different Subtypes




Pattern of CD30 expression in non-ALCL PTCLs



Brentuximab Vedotin in non-ALCL

- In a follow-up study of *non-ALCL*, CD30+ PTCL, patient were treated with BV at the same dosing regimen
- The ORR in this population had an ORR of 41%, including 24% CR with a median DOR of 6.4 months

PR 2 (15) 4 (19) 6 SD 3 (23) 3 (14) 6 PD 3 (23) 11 (52) 14 Objective response rate, n (%) 7 (54) 7 (33) 14 95% CI for objective response rate [±] 25.1, 80.8 14.6, 57 24.6				
CR 5 (38) 3 (14) 8 PR 2 (15) 4 (19) 6 SD 3 (23) 3 (14) 6 PD 3 (23) 11 (52) 14 Objective response rate, n (%) 7 (54) 7 (33) 14 95% CI for objective response rate [±] 25.1, 80.8 14.6, 57 24.6		AITL, n = 13	PTCL-NOS, n = 21	Total, N = 34
PR 2 (15) 4 (19) 6 SD 3 (23) 3 (14) 6 PD 3 (23) 11 (52) 14 Objective response rate, n (%) 7 (54) 7 (33) 14 95% CI for objective response rate [±] 25.1, 80.8 14.6, 57 24.0	est clinical response, n (%) [*]			
SD 3 (23) 3 (14) 6 PD 3 (23) 11 (52) 14 Objective response rate, n (%) 7 (54) 7 (33) 14 95% CI for objective response rate [±] 25.1, 80.8 14.6, 57 24.6	CR	5 (38 <mark>)</mark>	3 (14)	8 (24)
PD 3 (23) 11 (52) 14 Objective response rate, n (%) 7 (54) 7 (33) 14 95% CI for objective response rate [±] 25.1, 80.8 14.6, 57 24.0	PR	2 (15)	4 (19)	6 (18)
Objective response rate, n (%) 7 (54) 7 (33) 14 95% CI for objective response rate [±] 25.1, 80.8 14.6, 57 24.0	SD	3 (23)	3 (14)	6 (18)
95% CI for objective response rate ^{\pm} 25.1, 80.8 14.6, 57 24.0	PD	3 (23)	11 (52)	14 (41)
	jective response rate, n (%)	7 (54)	7 <mark>(</mark> 33)	14 (41)
Disease control rate, n (%) ^{\pm} 10 (77) 10 (48) 20	% CI for objective response rate $^{\pm}$	25.1, 80.8	14.6, 57	24.6, 59.3
	sease control rate, n (%) [±]	10 (77)	10 (48)	20 (59)



• FIL Phase II study: ORR 30.4%, median DOR 3.4 months

Phase 1 Study of BV in **Frontline** ALCL

VOLUME 32 \cdot NUMBER 28 \cdot OCTOBER 1 2014

JOURNAL OF CLINICAL ONCOLOGY

Brentuximab Vedotin in the Front-Line Treatment of Patients With CD30⁺ Peripheral T-Cell Lymphomas: Results of a Phase I Study

Michelle A. Fanale, Steven M. Horwitz, Andres Forero-Torres, Nancy L. Bartlett, Ranjana H. Advani, Barbara Pro, Robert W. Chen, Andrew Davies, Tim Illidge, Dirk Huebner, Dana A. Kennedy, and Andrei R. Shustov

	Sequential				Combination							
	AL (n =	CL		.CL = 19)		ALCL = 7)		otal = 26)				
Response	No.	%	No.	%	No.	%	No.	%				
Objective response	11	85	19	100	7	100	26	100				
Complete remission	8	62	16	84	7	100	23	88				
Partial remission	3	23	3	16	0		3	12				
Stable disease	0		0		0		0					
Progressive disease	2	15	0		0		0					

 Table 5. Best Response After Sequential or Combination Treatment

Phase 1: study. 39 patients with newly diagnosed PTCLs, 32 of which with systemic ALCL (6 ALK positive, 26 ALK negative)

Sequential treatment: BV for 2 cycles \rightarrow 6 cycles of CHOP


- **Combination** treatment: BV + CHP x 6 cycles
- All patient who responded to treatment received single agent BV for 8-10 additional cycles
- ORR 85% (11/13) for sequential
 - CR 62% (8/13)

• ORR 100% (19/19) for <u>combination</u>

- 84% CR (16/19)
- PFS 21.4 months (95%, CI 11.7 to not reached)

ECHELON-2: Brentuximab Vedotin + CHP vs CHOP in Previously Untreated CD30+ PTCL

Multicenter, randomized, double-blind, double dummy, active-controlled phase III trial



*PTCL includes sALCL (including ALK+ sALCL with IPI ≥ 2 and ALK- sALCL), PTCL-NOS, AITL, ATLL, EATL, HSTCL. Study targeted 75% (± 5%) ALCL in line with European regulatory commitment. [†]Brentuximab vedotin: 1.8 mg/kg. [‡]Cyclophosphamide 750 mg/m², doxorubicin 50 mg/m², vincristine 1.4 mg/m² (CHOP only), prednisone 100 mg on Days 1-5. G-CSF primary prophylaxis, consolidative RT, SCT per investigator discretion.

- Primary endpoint: PFS per BICR (SCT or RT consolidation not considered events)
- Secondary endpoints: OS, PFS per BICR in sALCL patients, CR, ORR, safety


ECHELON-2: Baseline Characteristics

Patient Characteristic	BV+CHP (n = 226)	CHOP (n = 226)
Male, n (%)	133 (59)	151 (67)
Median age, yrs (IQR)	58 (45–67)	58 (44–67)
IPI score, n (%)		
0-1	53 (23)	48 (21)
2-3	140 (62)	144 (64)
4-5	33 (15)	34 (15)
Stage III/IV, n (%)	184 (81)	180 (80)

Patient Characteristic	BV+CHP (n = 226)	CHOP (n = 226)
Disease diagnosis, n (%)		
sALCL	162 (72)	154 (68)
ALK+	49 (22)	49 (22)
ALK-	113 (50)	105 (46)
PTCL-NOS	29 (13)	43 (19)
AITL	30 (13)	24 (11)
ATLL	4 (2)	3 (1)
EATL	1 (0)	2 (1)

Approximately 70% of patients had sALCL

ECHELON-2: PFS and OS with BV + CHOP vs CHOP Alone in ALCL



Treatment	Events, n (%)	HR (95% CI)	P Value
BV+CHP	95 (42)	0.71	011
СНОР	124 (55)	(0.54-0.93)	.011


Treatment	Deaths, n (%)	HR (95% CI)	P Value
BV+CHP	51 (23)	0.66	.0244
СНОР	73 (32)	(0.46-0.95)	.0244

ECHELON-2: AEs

AE, n (%)	BV+CHP (n = 223)	CHOP (n = 226)	
Any AE	221 (99)	221 (98)	
Grade ≥ 3 AEs	147 (66)	146 (65)	
Serious AEs	87 (39)	87 (38)	
Death due to AEs	7 (3)	9 (4)	


Subjects, n (%)	BV+CHP (n=223)	CHOP (n=226)
Treatment-emergent PN	117 (52)	124 (55)
Resolution of all PN events	58 (50)	79 (64)
Ongoing PN at last follow up	61 (52)	45 (36)
Grade 1	44 (72)	32 (71)
Grade 2	15 (25)	12 (27)
Grade 3	2 (1)	1 (1)


AEs Occurring in \geq 20% of Patients



Horwitz S, et al. Lancet 2019. Horwitz S, et al. ASH 2018. Abstract 997.

ECHELON-2: PFS and OS by PTCL Subtypes





PFS and OS benefits greatest in patients with sALCL


Echelon-2 -Analysis by Subtypes: Estimated 5-year PFS and OS rates in prespecified subgroups

Subgroup	Estimated 5-y A+CHP	vear PFS rate CHOP	HR (95% CI)	P-value	Estimated A+CHP	5-year OS rate CHOP	HR (95% CI)	P-value
PTCL subtype			•					
PTCL-NOS <i>,</i> % (n)	26.5 (29)	25.7 (43)	0.79 (0.43, 1.43)	0.4	46.2 (29)	35.9 (43)	0.75 (0.37, 1.48)	0.4003
AITL, % (n)	26.6 (30)	48.1 (24)	1.41 (0.64, 3.11)	0.3958	67.8 (30)	62.5 (24)	1.01 (0.40, 2.55)	0.9855
sALCL								
Overall, % (n)	60.6 (162)	48.4 (154)	0.55 (0.39, 0.79)	0.0009	75.8 (162)	68.7 (154)	0.66 (0.43, 1.01)	0.0529
ALK+ % (n)	87 (49)	67 (49)	0.40 (0.17, 0.98)	0.0372	91.5 (26)	79.6 (27)	0.48 (0.16, 1.40)	0.1688
ALK– % (n)	49 (113)	39 (105)	0.58 (0.40, 0.86)	0.0054	68.7 (50)	63.3 (41)	0.71 (0.44, 1.12)	0.1373
sALCL, IPI Score								
0–1 <i>,</i> % (n)	59.5 (41)	47.6 (32)	0.42 (0.18, 0.94)	0.0301	87.0 (41)	86.2 (32)	0.73 (0.20, 2.73)	0.6411
2–3 <i>,</i> % (n)	68.5 (95)	50.9 (100)	0.57 (0.35, 0.90)	0.0158	80.6 (95)	68.7 (100)	0.57 (0.32, 1.01)	0.0496
₄–5 <i>,</i> % (n)	27.2 (26)	36.4 (22)	0.73 (0.35, 1.50)	0.3839	38.0 (26)	43.2 (22)	0.89 (0.42, 1.89)	0.7606

intent-to-treat; IPI, International Prognostic Index

Horwitz S, et al. ASH 2021

Frontline Therapy with BV-CHEP + BV Maintenance (n=46)




Response assessment by investigators: 2014 Lugano classification

Response to CHEP-BV


	All Patients (n=46)		Response		Non-ALCL		PTCL NOS	
Response	Interim	End of CHEP-BV		(n=16)	(n=30)	(n=17)	(n=11)	(n=2)
Overall response (ORR)	44 (96%)	42 (91%)	ORR	15 (94%)	27 (90%)	16 (94%)	9 (82%)	2 (100%)
• • •			CR	15 (94%)	22 (73%)	14 (82%)	6 (55%)	2 (100%)
Complete response (CR)	27 (59%)	37 (80%)	PR	0	5	2	3	0
Partial response (PR)	17	5			5	2	5	0
Stable disease (SD)	1	0	SD	0	0	0	0	0
Progressive disease (PD)	1	4	PD	1	3	1	2	0

PFS from treatment start in subgroups

- 18mo PFS: ALCL 81% vs non-ALCL 49%
 - ALCL (n=16): ASCT 7 vs no 9
 - Non-ALCL (n=32): ASCT 17 vs no 15




- 18mo PFS: AITL 48%, PTCL NOS 51%
 - AITL (n=18): ASCT 12 vs no 6
 - PTCL NOS (n=11): ASCT 4 vs no 7



PFS from treatment start by CD30%

- 18mo PFS by CD30% (non-ALCL)
 - CD30 1-9% (n=15): 43%
 - CD30 ≥ 10% (n=17): 55%



Conclusions

- $R/R : BV \rightarrow$ high CR rate, improved PFS/OS in sALCL
 - Role in non-ALCL
 - Retreatment vs prolonged treatment/ maintenance
- 1L : <u>BV-CHP</u> improves PFS /OS \rightarrow new SOC
 - Difference most pronounced in ALCL
 - Less pronounced with AITL or PTCL

-Role of CD30 positivity/Need alternative strategies

- Consolidation with ASCT
 - <u>CHEP-BV</u> tolerable and high CR rate
- CHEP-BV + ASCT + BV consolidation associated with excellent PFS→ merits further study

Thank you! Grazie



2018...2022 T-Cell Lymphomas: Finally vision and mission!

